If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
=== Economic Sciences === The medal for the Nobel Memorial Prize in Economic Sciences was designed by Gunvor Svensson-Lundqvist in 1968. The obverse of the medal depicts Alfred Nobel and the words "Sveriges Riksbank till Alfred Nobels Minne 1968" ("The Sveriges Riksbank, in memory of Alfred Nobel, 1968") with the symbol of the Sveriges Riksbank, the horn of plenty, displayed below. The name of the recipient is inscribed on the edge of the medal. The reverse features the emblem of the Royal Swedish Academy of Sciences, the North Star, in a design from 1815. "Kungliga Vetenskaps Akademien" ("The Royal Swedish Academy of Sciences") is inscribed around the edge of the star. It is the only medal without a quotation on its reverse. Since 2012 the economics medal has been manufactured by Svenska Medalj in Eskilstuna.
The neurotransmitter serotonin, a non-selective serotonin receptor agonist, strongly increases oxytocin levels, by up to 12-fold, when given via intracerebroventricular injection in rodents. This can be blocked by various serotonin receptor antagonists. Selective serotonin 5-HT1A receptor agonists like 8-OH-DPAT, buspirone, and ipsapirone increase oxytocin levels in rodents. Both 8-OH-DPAT and buspirone maximally increased oxytocin levels by around 9-fold, whereas ipsapirone increased oxytocin levels by only around 3-fold. Similarly to serotonin 5-HT1A receptor agonists, the serotonin 5-HT2 receptor agonist DOI increases oxytocin levels in rodents, with a maximal increase of around 5- to 10-fold depending on the dose. The serotonin 5-HT2A receptor antagonist ketanserin reduced the increase in oxytocin levels induced by DOI by about 90%, while addition of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor antagonist LY-53857 fully blocked the increase. The non-selective but preferential serotonin 5-HT2C receptor agonist meta-chlorophenylpiperazine (mCPP) maximally increased oxytocin levels by around 6-fold, with the increases minimally affected by ketanserin but abolished by non-selective serotonin 5-HT2 receptor antagonists including LY-53857, mianserin, and metergoline. Another non-selective but preferential serotonin 5-HT2C receptor agonist, MK-212, robustly increases oxytocin levels in rodents as well. The serotonin 5-HT3 receptor agonists SR-57277 and m-CPBG and the serotonin 5-HT4 receptor agonist RS-67506 increase oxytocin levels maximally by several-fold in rodents.
=== Drugs that cause QT prolongation === The main groups of drugs that can cause QT prolongation are antiarrhythmic medications, psychiatric medications, and antibiotics along with other drugs like antivirals and antifungals. However, the risk of TdP from these medications vary, and are often stratified by their known risk, possible risk, or conditional risk. The FDA provides guidance on QTc prescription drug labeling.
Sources: en.wikipedia.org
== Split == Chechens mediated in the settlement of the conflict between Jabhat al-Nusra (now — Hayat Tahrir al-Sham) and the Syrian opposition, on the one hand, and with ISIS, on the other. In early November 2014, the leadership of Jaish al-Muhajireen wal-Ansar, represented by Salahuddin Shishani, met with the leadership of ISIS in their capital Raqqa and held talks on reconciliation of the two warring parties. However, the conversation with the leadership of ISIS ended in vain as they chose to continue the conflict. In response to Shishani's proposal to stop the war between Sunni Muslims, in particular with Islamic Jamaats such as Jabhat al-Nusra, Ahrar al-Sham and others, the leadership of ISIS refused and stated that it would not stop fighting these groups, because it considers the emirs of these factions Kafirs and Murtads. After that, Shishani left Raqqa and returned to Idlib. This conflict was also reflected among the Chechen Mujahideen in Syria, in particular among the Chechen emirs, who had previously acted in alliance with each other. Some of them defected to the Islamic State and took leadership positions, while some remained on the side of Jabhat al-Nusra and the Syrian opposition. The very history of the conflict between Jabhat al-Nusra and ISIS (at that time, the Islamic State of Iraq) begins in the spring of 2013, when the emir of the Islamic State of Iraq which was Abu Bakr al-Baghdadi decided to expand his organisation into neighbouring Syria and to unite his territories in both the countries of Iraq and Syria.
Protonitazepyne (N-pyrrolidino protonitazene) is a benzimidazole derivative with opioid effects, which has been sold as a designer drug over the internet, first being mentioned in mid 2022 and definitively identified in drug seizures in Canada in early 2023 and Ireland in late 2023. It has since been identified by CanTEST in May 2024 in Australia and in late 2025 in Brazil by the State University of Campinas poison control center. It is an analogue of protonitazene where the N,N-diethyl group has been substituted for pyrrolidine group. While formal studies into its pharmacology have yet to be carried out, it has an in vitro potency approximately 350x times that of morphine.
As of August 13, 2020, the menu underwent another update as part of their efforts to streamline processes in their restaurants in response to the COVID-19 pandemic, discontinuing the following items: Grilled Steak Soft Taco; 7-Layer Burrito; Nachos Supreme; Beefy Fritos Burrito; Spicy Tostada; Triple Layer Nachos; Cheesy Fiesta Potatoes; Loaded Grillers, both Cheesy Potato and Beefy Nacho; Chips & Dips; and Mini Skillet Bowl.
Sources: en.wikipedia.org
=== Recognition === Recognition of stop codons in bacteria have been associated with the so-called 'tripeptide anticodon', a highly conserved amino acid motif in RF1 (PxT) and RF2 (SPF). Even though this is supported by structural studies, it was shown that the tripeptide anticodon hypothesis is an oversimplification.
== See also == Rec. 2020 – ITU-R Recommendation for UHDTV 4K resolution – Resolutions of common 4K formats and list of 4K-monitors, TVs, projectors 8K resolution – Specifications for ~8x4K UHD and 8Kx8K fulldome Ultra HD Blu-ray – 2160p / 4K (3840 × 2160 resolution) format Blu-ray Disc as specified by Blu-ray Disc Association IMAX – A film theater format that historically has been innovative in creating a more realistic viewing experience High Efficiency Video Coding (HEVC) VP9 / WebM 22.2 surround sound – The audio component of Super Hi-Vision
The four substrates of this enzyme are 7-methylxanthine, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are xanthine, oxidised NAD+, water, and formaldehyde. The enzyme is a non-heme iron protein that is part of the pathway of caffeine degradation in Pseudomonas putida.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.